Literature DB >> 20347683

Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage.

Caren Randon1, Bart Jacobs, Frederik De Ryck, Hilde Beele, Frank Vermassen.   

Abstract

OBJECTIVE: The availability of autologous vein grafts remains the limiting factor in infragenual bypass surgery in many patients with critical limb ischemia (CLI). Alternatives such as prosthetic conduits are known to have a poor outcome and most are not resistant to infection. Based on previous experimental work, we started to use cryopreserved saphenous vein allografts for this indication 15 years ago. To evaluate their outcome, we performed a retrospective study of those bypasses with distal anastomosis on a crural or pedal vessel.
METHODS: Between November 1991 and December 2005, 108 cryopreserved great saphenous vein allografts were implanted for in 92 patients (42 women, 50 men) with a mean age of 71 years (range, 39-88 years). All patients received low-dose immunosuppressive therapy for up to 1 year after intervention. Follow-up was conducted until amputation, death, or the end of the study in March 2007.
RESULTS: Nondiabetic atherosclerosis the cause of CLI in 57%, 41% had diabetes, and 2% had Buerger disease. Forty-one conduits were performed for primary reconstructions and 67 for redo reconstructions. During a mean follow-up of 26.4 months, 69 occlusions occurred. Primary and secondary patency rates were 56% and 73% at 1 year, 32% and 60% at 3 years, and 17% and 38.5% at 5 years. Survival rates were 87.4% at 1 year and 64.5% at 5 years. At multivariate analysis, the intake of statins was predictive for improved patency (hazard ratio [HR], 0.09; P = .024) and for prolonged survival (HR, 0.335; P = .045). The presence of diabetes showed a trend for inferior patency (HR, 2.325; P = .116) and for decreased amputation risk (HR, 0.592; P = .078).
CONCLUSION: Cryopreserved saphenous vein allografts are a valuable alternative to prosthetic materials when autologous veins are not available. Our limb salvage and patency rates are higher then those described for prosthetic grafts at the infrapopliteal level in most studies. Moreover, these grafts are resistant to infection when performed for revascularization in patients with an infected ulcer. Better graft and patient selection, better graft surveillance and immunologic matching, and standard use of statins could possibly improve the results even further. Shortage in availability might be a limiting factor for their widespread use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347683     DOI: 10.1016/j.jvs.2009.11.062

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

1.  Neointimal hyperplasia in allogeneic and autologous venous grafts is not different in nature.

Authors:  Albert Busch; Elena Hartmann; Nicole Wagner; Süleyman Ergün; Ralph Kickuth; Richard Kellersmann; Udo Lorenz
Journal:  Histochem Cell Biol       Date:  2015-03-19       Impact factor: 4.304

2.  Preimplantation processing of ex vivo-derived vascular biomaterials: effects on peripheral cell adhesion.

Authors:  Joseph S Uzarski; Aurore B Van De Walle; Peter S McFetridge
Journal:  J Biomed Mater Res A       Date:  2012-07-24       Impact factor: 4.396

3.  Defining utility and predicting outcome of cadaveric lower extremity bypass grafts in patients with critical limb ischemia.

Authors:  Catherine K Chang; Salvatore T Scali; Robert J Feezor; Adam W Beck; Alyson L Waterman; Thomas S Huber; Scott A Berceli
Journal:  J Vasc Surg       Date:  2014-07-16       Impact factor: 4.268

4.  Management of infrapopliteal peripheral arterial occlusive disease.

Authors:  Warren J Gasper; Sara J Runge; Christopher D Owens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-04

Review 5.  Bioengineering Human Tissues and the Future of Vascular Replacement.

Authors:  Mehmet H Kural; Yuling Li; Juan Wang; Kaleb M Naegeli; Emmanuelle A Hugentobler; Laura E Niklason
Journal:  Circ Res       Date:  2022-06-23       Impact factor: 23.213

6.  Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats.

Authors:  Katrin Splith; Peter Fellmer; Ivan Matia; Martin Varga; Martin Oliverius; Stephanie Kuhn; Linda Feldbrügge; Felix Krenzien; Hans-Michael Hau; Georg Wiltberger; Moritz Schmelzle; Sven Jonas
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 7.  Optimal management of infrainguinal arterial occlusive disease.

Authors:  David J Pennywell; Tze-Woei Tan; Wayne W Zhang
Journal:  Vasc Health Risk Manag       Date:  2014-10-24

8.  Cryopreserved Human Allografts for the Reconstruction of Aortic and Peripheral Prosthetic Graft Infection.

Authors:  Matteo Bossi; Matteo Tozzi; Marco Franchin; Stefania Ferraro; Nicola Rivolta; Massimo Ferrario; Chiara Guttadauro; Patrizio Castelli; Gabriele Piffaretti
Journal:  Ann Vasc Dis       Date:  2017-12-25

Review 9.  Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.

Authors:  Hannah A Strobel; Elisabet I Qendro; Eben Alsberg; Marsha W Rolle
Journal:  Front Pharmacol       Date:  2018-11-21       Impact factor: 5.810

10.  Delivery of targeted gene therapies using a hybrid cryogel-coated prosthetic vascular graft.

Authors:  Frank LoGerfo; Leena Pradhan-Nabzdyk; Cindy Huynh; Ting-Yu Shih; Alexander Mammoo; Amruta Samant; Saif Pathan; David W Nelson; Christiane Ferran; David Mooney
Journal:  PeerJ       Date:  2019-08-20       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.